Literature DB >> 22460137

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

D E Furst1, E C Keystone, J Braun, F C Breedveld, G R Burmester, F De Benedetti, T Dörner, P Emery, R Fleischmann, A Gibofsky, J R Kalden, A Kavanaugh, B Kirkham, P Mease, J Sieper, N G Singer, J S Smolen, P L C M Van Riel, M H Weisman, K Winthrop.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22460137     DOI： 10.1136/annrheumdis-2011-201036

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  28 in total

1.  [Biologicals 2012].

Authors:  M Gaubitz
Journal:  Orthopade       Date:  2012-07       Impact factor: 1.087

2.  The fundamental unit of pain is the cell.

Authors:  David B Reichling; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2013-12       Impact factor: 6.961

3.  [Biosimilars : Current state of the build up to series production].

Authors:  M Aringer; T Dörner
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

4.  Infectious complications of immune modulatory agents.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

5.  Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.

Authors:  Gabriel Dischereit; Ingo H Tarner; Ulf Müller-Ladner; Uwe Lange
Journal:  Clin Rheumatol       Date:  2012-11-24       Impact factor: 2.980

Review 6.  Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Amy S Mudano; Elizabeth Tanjong Ghogomu; Maria E Suarez-Almazor; Rachelle Buchbinder; Lara J Maxwell; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 7.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 8.  Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.

Authors:  Ioannis Androulakis; Christos Zavos; Panagiotis Christopoulos; George Mastorakos; Maria Gazouli
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

Review 9.  Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.

Authors:  Herma H Fidder; Maartje M J Singendonk; Mike van der Have; Bas Oldenburg; Martijn G H van Oijen
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

Review 10.  Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Ahmed Kotb; Robin Christensen; Amy S Mudano; Lara J Maxwell; Nipam P Shah; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2016-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.